Royalty Pharma Acquires Royalty Interest in Cliramitug from Neurimmune

Marco Zingaro Europe Legal Chronicle
Tagged:

VISCHER has advised Royalty Pharma Investments. Mintz and Schellenberg Wittmer have advised Neurimmune AG. Royalty Pharma Investments has acquired a portion of Neurimmune AG’s royalty interest…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Marco Zingaro

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here